Literature DB >> 27485170

Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

L Schirmer1, V Worthington2, U Solloch3, V Loleit1, V Grummel1, N Lakdawala2, D Grant2, R Wassmuth4,5, A H Schmidt3,4, F Gebhardt6, T F M Andlauer7,8, J Sauter3, A Berthele1, M P Lunn2, Bernhard Hemmer9,10.   

Abstract

Few regional and seasonal Guillain-Barré syndrome (GBS) clusters have been reported so far. It is unknown whether patients suffering from sporadic GBS differ from GBS clusters with respect to clinical and paraclinical parameters, HLA association and antibody response to glycosphingolipids and Campylobacter jejuni (Cj). We examined 40 consecutive patients with GBS from the greater Munich area in Germany with 14 of those admitted within a period of 3 months in fall 2010 defining a cluster of GBS. Sequencing-based HLA typing of the HLA genes DRB1, DQB1, and DPB1 was performed, and ELISA for anti-glycosphingolipid antibodies was carried out. Clinical and paraclinical findings (Cj seroreactivity, cerebrospinal fluid parameters, and electrophysiology) were obtained and analyzed. GBS cluster patients were characterized by a more severe clinical phenotype with more patients requiring mechanical ventilation and higher frequencies of autoantibodies against sulfatide, GalC and certain ganglioside epitopes (54 %) as compared to sporadic GBS cases (13 %, p = 0.017). Cj seropositivity tended to be higher within GBS cluster patients (69 %) as compared to sporadic cases (46 %, p = 0.155). We noted higher frequencies of HLA class II allele DQB1*05:01 in the cluster cohort (23 %) as compared to sporadic GBS patients (3 %, p = 0.019). Cluster of severe GBS was defined by higher frequencies of autoantibodies against glycosphingolipids. HLA class II allele DQB1*05:01 might contribute to clinical worsening in the cluster patients.

Entities:  

Keywords:  Autoantibodies; Campylobacter jejuni; Glycosphingolipids; Guillain–Barré syndrome (GBS); HLA class II alleles

Mesh:

Substances:

Year:  2016        PMID: 27485170     DOI: 10.1007/s00415-016-8237-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  46 in total

1.  Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands.

Authors:  R Van Koningsveld; P A Van Doorn; P I Schmitz; C W Ang; F G Van der Meché
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

2.  Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP.

Authors:  Eleni E Magira; Miltiadis Papaioakim; Irving Nachamkin; Arthur K Asbury; Chun Y Li; Tony W Ho; John W Griffin; Guy M McKhann; Dimitri S Monos
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

3.  Association of HLA-DR/DQ polymorphisms with Guillain-Barré syndrome in Tunisian patients.

Authors:  Najiba Fekih-Mrissa; Meriem Mrad; Anis Riahi; Aicha Sayeh; Jamel Zaouali; Nasreddine Gritli; Ridha Mrissa
Journal:  Clin Neurol Neurosurg       Date:  2014-03-19       Impact factor: 1.876

Review 4.  Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding.

Authors:  S Rinaldi; K M Brennan; H J Willison
Journal:  Prog Lipid Res       Date:  2009-09-06       Impact factor: 16.195

5.  Conduction block in acute motor axonal neuropathy.

Authors:  Norito Kokubun; Momoka Nishibayashi; Antonino Uncini; Masaaki Odaka; Koichi Hirata; Nobuhiro Yuki
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

6.  Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

7.  HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome.

Authors:  K Geleijns; G M Th Schreuder; B C Jacobs; K Sintnicolaas; R van Koningsveld; J Meulstee; J D Laman; P A van Doorn
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

8.  Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome.

Authors:  C W Ang; A P Tio-Gillen; J Groen; P Herbrink; B C Jacobs; R Van Koningsveld; A D M E Osterhaus; F G A Van der Meché; P A van Doorn
Journal:  J Neuroimmunol       Date:  2002-09       Impact factor: 3.478

9.  Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies.

Authors:  A Chiba; S Kusunoki; H Obata; R Machinami; I Kanazawa
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

10.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

View more
  5 in total

Review 1.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

Review 2.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

3.  Young woman with Guillain-Barré syndrome and cervical transverse myelitis-A new GBS variant, not coincidence.

Authors:  Jenna Gharzeddine; Brian Renner; Natalie Wassall; Kristen Tran; Antonio Liu
Journal:  Clin Case Rep       Date:  2020-04-21

4.  Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.

Authors:  Christine A Garcia; Alex El-Ali; Tanya J Rath; Lydia C Contis; Vikram Gorantla; Jan Drappatz; Diwakar Davar
Journal:  J Immunother Cancer       Date:  2018-08-31       Impact factor: 13.751

5.  HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome.

Authors:  Gian Luigi Gigli; Alberto Vogrig; Annacarmen Nilo; Martina Fabris; Alessia Biasotto; Francesco Curcio; Valeria Miotti; Carlo Tascini; Mariarosaria Valente
Journal:  Neurol Sci       Date:  2020-12       Impact factor: 3.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.